NASDAQ · Biotechnology

LPCN (LPCN) Stock

$2.14 +2.88% NASDAQ: LPCN Healthcare

Valuation

MetricValue
Price$2.14
Market Cap$12.42M
P/E Ratio-1.35
P/B Ratio0.75
P/S Ratio6.61
EPS (TTM)$-1.69
52-Week High$12.37
52-Week Low$1.81
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-54.41%
ROA-33.07%
ROCE-71.43%
Gross Margin-8.21%
Operating Margin-6.06%
Net Margin-5.71%
Debt/Equity0.00
Current Ratio5.67

Annual Financials (USD)

Metric20212022202320242025
Revenue$16.0M$1.0M$-3.0M$11.0M$2.0M
Operating Profit$3.0M$-12.0M$-18.0M$-1.0M$-10.0M
Net Profit$-1.0M$-11.0M$-16.0M$0$-10.0M
EPS$-0.12$-2.05$-3.14$0.00$-1.69
Op Margin19.5%-2423.9%629.0%-10.3%-524.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$52.0M$38.0M$23.0M$23.0M$17.0M
Total Liabilities$7.0M$2.0M$3.0M$2.0M$3.0M
Cash$3.0M$3.0M$5.0M$6.0M$5.0M
Borrowings$2.0M$0$0$0$0

Latest News

Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154 PR Newswire · Jun 4, 2026 Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting PR Newswire · May 19, 2026 Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase PR Newswire · May 18, 2026 Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 PR Newswire · May 7, 2026 Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates Zacks · May 7, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-4.0M$-12.0M$-12.0M$-1.0M$-10.0M
Investing Cash Flow$-44.0M$14.0M$13.0M$2.0M$6.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-21.0M$0$2.0M$1.0M$-1.0M
Free Cash Flow$-4.0M$-12.0M$-12.0M$-1.0M$-10.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA0.51
FCF Yield-75.94%
Quick Ratio9.99
Interest Coverage—
Return 1Y-25.56%
Return 3Y-46.61%
Return 5Y-88.98%

Ownership

Insiders Held4.51%
Institutions Held44.29%
Institutions Float Held46.38%
Institutional HolderSharesReport Date
Ikarian Capital, LLC508,5562026-03-31
Squadron Capital Management LLC450,0002026-03-31
Eversept Partners, LP294,9892026-03-31
Rosalind Advisors, Inc.221,6162026-03-31
AIGH Capital Management LLC200,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADAPAdaptimmune Therapeutics plc $0.05 -3.00% -0.16 $75.16M 0.00%
ANLAdlai Nortye Ltd. $13.26 +2.00% -8.19 $703.84M 0.00%
BLRXBioLineRx Ltd. $2.85 -2.45% -1.36 $12.39M 0.00%
EDSA $5.35 +1.90% -8.61 $51.54M 0.00%
ERNA $3.35 -3.46% 0.01 $1.05M 0.00%

About LPCN

LPCN is led by CEO Mahesh V. Patel, publicly traded since 2013.

LPCN stock trades at $2.14 with a market capitalization of $12.42M. The stock is valued at a price-to-earnings (P/E) ratio of -1.35, price-to-book of 0.75, price-to-sales of 6.61. Over the past 52 weeks the stock has ranged between $1.81 and $12.37, and currently trades 82.7% below its 52-week high.

On profitability, LPCN generates a return on equity (ROE) of -54.41%, return on capital employed of -71.43%, an operating margin of -6.06%, a net profit margin of -5.71%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides